Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical is viewed positively because its core musculoskeletal business is delivering durable share gains, with U.S. Spine growing 10% for a third consecutive quarter and trauma up 30%+ in Q1, while international spine also advanced 16.4% as reported. The company’s operating profile is strengthening at the same time, as Q1 revenue of $760MM beat expectations, gross margin reached 69.2%, adjusted EBITDA margin was 32.3%, and EPS of $1.12 rose 65% y/y, supporting the raised 2026 EPS guide of $4.70-$4.80. Its long-term outlook is further reinforced by ExcelsiusGPS adoption, a pivot toward recurring revenue in Enabling Technologies, and a debt-free balance sheet with $799MM in cash, all of which suggest room for continued beat-and-raise execution.

Globus Medical is exposed to elevated fundamental risk because medical device companies face stringent product-quality requirements and greater recall liability, which can pressure operating performance and investor confidence. The recent Nevro step back, with 1Q26 sales of $83M down 17% Q/Q and adjusted EBITDA margin falling to 11.8% from 21.2% in 4Q25, highlights how integration initiatives and commercial disruption can quickly weigh on execution. A bear case assuming revenue growth slows to low-single-digits with flat margins, alongside risks from slower spine growth, merger dis-synergies, weaker Enabling Technologies sales, and margin pressure, supports a negative outlook.